A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of LNK01001 Capsule in Moderately to Severely Active Rheumatoid Arthritis Patients With Inadequate Response or Intolerance to csDMARDs
Latest Information Update: 02 Jan 2024
At a glance
- Drugs LNK 01001 (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Lynk Pharmaceuticals
- 15 Nov 2023 Results assessing the 24-week efficacy and safety results of LNK01001 in patients with moderate to severe active RA who had an inadequate response to csDMARDs, were presented at the ACR Convergence 2023.
- 24 Oct 2023 Status changed from recruiting to completed.
- 16 May 2023 Results published in Lingke Pharmaceuticals media release.